Tezepelumab (Tezspire®). HTA ID: 23025

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 23025
Drug Tezepelumab
Brand Tezspire®
Indication Tezepelumab (Tezspire®) is indicated as add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma, who are inadequately controlled despite high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.
Assessment Process
Rapid review commissioned 10/05/2023
Rapid review completed 15/06/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that tezepelumab not be considered for reimbursement at the submitted price*.
Full pharmacoeconomic assessment commissioned by HSE 01/02/2024
Pre-submission consultation with Applicant 05/03/2024

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.